吴卫平.重症肌无力//蒲传强，吴卫平，郎森阳.神经系统感染免疫学.北京：科学出版社，2003：449-452.

许贤豪.重症肌无力//匡培根.神经系统疾病药物治疗学.北京：人民卫生出版社，2008：877-892.

刘卫彬，夏强，门丽娜，等.以声带麻痹为突出表现的重症肌无力7例.中华医学杂志，2006，86（25）：1778-1780.

刘卫彬，门丽娜，何雪桃，等.我国南方1520例重症肌无力患者的临床特点.中国神经免疫学和神经病学杂志，2006，13（6）：326-330.

刘卫彬，丰岩清，曾樱，等.伴耳鸣和听力下降的重症肌无力：附7例报告.中国神经精神疾病杂志，2006，32（5）：461-463.

刘卫彬，门丽娜，夏强，等.疑难病例析评第91例味觉丧失-排便困难-复视-呼吸困难.中华医学杂志，2005，85（46）：3301-3303.

欧昶毅，刘卫彬，冯慧宇，等.重症肌无力伴发特发性甲状旁腺功能减退症二例.中国神经免疫学和神经病学杂志，2011，18（5）：377-378.

邱力刘卫彬.眼睑下垂-吞咽困难-肢体震颤--行走困难（疑难病例析评）.中华医学杂志，2013，93（27）：2170-2173.

Aragonés，JM，Bolíbar I，Bonfill X，et al.Myasthenia Gravis.A higher than expected incidence in the elderly.Neurology，2003，60：1024-1026.

Barnett C，Katzberg H，NabaVi M，et al.The quantitative myasthenia Gravis score：comparison with clinical，electrophysiological，and laboratory markers.J Clin Neuromuscul Dis，2012，13（4）：201-205.

Chan KH，Cheung RT，Mak W，et al.Nonthymoma early-onset-and late-onset-generalized myasthenia Gravis--a retrospective hospital-based study.Clin Neurol Neurosurg，2007，109（8）：686-691.

Christensen PB.Associated autoimmune disease in myasthenia Gravis.A population-based study.Acta Neurol Scand，1995，91：192-195.

EVoli A，Minisci C，Di Schino C，et al.Thymoma in patients with MG：characteristics and longterm outcome.Neurology，2002，59：1844-1850.

Ropper AH，Samuels MA.Other somatic sensation.//Ropper AH，Samuels MA.Adams and Victor’s Principles of Neurology.9th ed.New York：McGraw-Hill Medical，2009.

Grob D，Brunner N，Namba T，et al.Lifetime course of myasthenia Gravis.Muscle Nerve，2008，37：141-149.

Huang X，Liu WB，Men LN，et al.Clinical features of myasthenia gravis in southern China：a retrospective review of 2，154cases over 22years.Neurol Sci，2013，34（6）：911-917.

Kuks J B.M.Clinical Presentation and Epidemiology of Myasthenia Gravis.Current Clinical Neurology，Myasthenia Gravis and Related Disorders，79-94.Kaminski HJ，Humana Press，New York，2009.

Kabasawa C，Shimizu Y，Suzuki S，et al.Taste disorders in myasthenia Gravis：a multicenter cooperative study.Eur J Neurol，2012，31：1468

Masuda T，Motomura M，Utsugisawa K，et al.Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. Journal of Neurology，Neurosurgery ＆Psychiatry，2012，83（9）：935-940.

McGrogan A，Sneddon S，de Vries CS.The incidence of myasthenia Gravis：a systematic literature review.Neuroepidemiology，2010，34（3）：171-183.

Meriggioli MN，Sanders DB.Autoimmune myasthenia Gravis：emerging clinical and biological heterogeneity.Lancet Neurol，2009，8（5）：475-490.

Mygland A，Aarli JA，Matre R，et al.Ryanodine receptor antibodies related to severity of thymoma associated myasthenia Gravis.J Neurol Neurosurg Psychiatry，1994，57（7）：843-846.

Niks EH，Kuks JBM，Verschuuren JJGM.Epidemiology of myasthenia Gravis with anti-muscle specific kinase antibodies in the Netherlands.J Neurol Neurosurg Psychiatry，2007，78（4）：417-418.

Osserman KE.Myasthenia Gravis.New York：Grune ＆Stratton，1958.

Osserman KE，Genkins G.Studies in myasthenia Gravis：review of a twenty year experience in over 1200patients.Mt Sinai J Med，1971，34：497-537.

Oosterhuis HJ.The natural course of myasthenia Gravis：a long term follow up study.J Neurol Neurosurg Psychiatry，1989，52：1121-1127.

Potagas C，Dellatotas G，Tavernarakis A，et al.Myasthenia Gravis：changes observed in a 30-years retrospective clinical study of a hospital-based population.J Neurol，2004，251（1）：116-117.

Pasutharnchat N，Wacharapluesadee S，Hemachudha T.Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia Gravis.J Med Assoc Thai，2012，95（3）：313-319.

Rotstein DL，Bril V.A family with myasthenia Gravis with and without thymoma.Can J Neurol Sci，2012，39（4）：539-540

Romi F，Skeie GO，Gilhis NE，et al.Striational antibodies in myasthenia Gravis.Arch Neurol，2005，62：442-446.

Romi F，Skeie GO，Aarli JA，et al.The severity of myasthenia Gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.Arch Neurol，2000，57：1596-1600.

Romi F，Aarli JA，Gilhus NE.Myasthenia Gravis patients with ryanodine receptor antibodies have distinctive clinical features.Eur J Neurol，2007，14：617-620.

Romi F，Gilhus NE，Varhaug JE，et al.Disease severity and outcome in thymoma myasthenia：a long-term observational study.Eur J Neurol，2003，10：701-706.

Somnier FE.Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia Gravis.Neurology，2005，65：928-930.

Skeie GO，Romi F.Paraneoplastic myasthenia Gravis：immunological and clinical aspects.Eur J Neurol，2008，15：1029-1033.

Sanders DB，Juel VC.MuSK-antibody positive myasthenia Gravis：questions from the clinic.J Neuroimmunol，2008，201-202：85-89..

Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America，Jartezki A，Barohn RJ，et al.Myasthenia Gravis.Recommendations for clinical research standards.Neurology，2000，55：16-23

Tola MR，Caniatti LM，Casetta I，et al.Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia Gravis：apopulation based survey in the province of Ferrara，northern Italy.Acta Neurol Scand，1994，90：318-323.

Zhang X，Yang M，Xu J，et al.Clinical and serological study of myasthenia Gravis in HuBei Province，China.J Neurol Neurosurg Psychiatry，2007，78：386-390.

Zivkovi SA，Clemens PR，Lacomis D.Characteristics of late-onset myasthenia Gravis.J Neurol，2012，259（10）：2167-2171.